Abstract
In human neuroblastoma cell cultures, non-human primates and human beings, L-serine is neuroprotective, acting through a variety of biochemical and molecular mechanisms. Although L-serine is generally classified as a non-essential amino acid, it is probably more appropriate to term it as a “conditional non-essential amino acid” since, under certain circumstances, vertebrates cannot synthesize it in sufficient quantities to meet necessary cellular demands. L-serine is biosynthesized in the mammalian central nervous system from 3-phosphoglycerate and serves as a precursor for the synthesis of the amino acids glycine and cysteine. Physiologically, it has a variety of roles, perhaps most importantly as a phosphorylation site in proteins. Mutations in the metabolic enzymes that synthesize L-serine have been implicated in various human diseases. Dosing of animals with L-serine and human clinical trials investigating the therapeutic effects of L-serine support the FDA’s determination that L-serine is generally regarded as safe (GRAS); it also appears to be neuroprotective. We here consider the role of L-serine in neurological disorders and its potential as a therapeutic agent.
Original language | English |
---|---|
Pages (from-to) | 213-221 |
Number of pages | 9 |
Journal | Neurotoxicity Research |
Volume | 33 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2018 |
Externally published | Yes |
Keywords
- ALS
- Alzheimer’s Disease
- L-serine
- Neurodegeneration
- Neuroprotection
- Therapy